Bictegravir

Gilead and Merck's Phase 2 study shows islatravir and lenacapavir maintained high viral suppression in HIV-1 patients at 48 weeks, with no viral load >50 copies/mL. Adverse events were minimal, with 19.2% in ISL + LEN group and 5.8% in Biktarvy group experiencing treatment-related issues.

Gilead and Merck announce Phase 2 study results showing islatravir and lenacapavir combination maintained 94.2% viral suppression at 48 weeks, advancing to Phase 3 for potential weekly oral HIV treatment.

Gilead and Merck report Phase 2 data showing a treatment switch to an investigational oral once-weekly combination of islatravir and lenacapavir maintained viral suppression in adults at Week 48, with 94.2% of participants achieving HIV-1 RNA <50 copies/mL.

HIVR4P 2024 conference highlights safety of dapivirine vaginal ring during early pregnancy, no interactions between long-acting injectable cabotegravir (CAB-LA) PrEP and long-acting reversible contraceptives (LARCs), early-stage HIV vaccine findings showing potential to generate broadly neutralizing antibodies, discovery of monocytes expressing IL1B associated with smaller HIV reservoirs, and a novel refillable controlled-release antiretroviral drug implant for PrEP and ART.

Gilead Sciences to present new findings from antiviral research at IDWeek 2024, including data from HIV, COVID-19, and viral hepatitis studies, highlighting commitment to treating and preventing viral diseases.

Gilead signs royalty-free licensing agreements with six generic drugmakers to produce and sell its HIV drug lenacapavir in resource-limited countries. The company plans to seek regulatory approval for lenacapavir as a preventive treatment, prioritizing applications in 18 high-burden countries in Africa and Southeast Asia. Lenacapavir, already approved for multi-drug resistant HIV in the U.S. and Europe, aims to expand access to prevention and treatment in lower-income regions.

Gilead Sciences discusses its focus areas in virology, oncology, and inflammation/immunology, highlighting successful data in HIV prevention with lenacapavir. The company also mentions progress in its liver franchise and oncology portfolio, including the potential launch of a BCMA cell therapy. Gilead expects growth driven by new product launches and anticipates sharing more data later this year.